Molecule
Molecule
molucle img

Chemistry at the Core

We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.

An elderly couple enjoying a peaceful day on the beach. An elderly couple enjoying a peaceful day on the beach. An elderly couple enjoying a peaceful day on the beach.
molucle img

Built for Patients

We partner with physician-scientists to identify patient needs and the limitations of existing therapies.

Driven by Purpose

We are passionate about using our expertise to address the needs of patients with cancer.

Ruth Adams

Ruth Adams

Vice President, Clinical Operations
Kari Andrews

Kari Andrews

Clinical
Kristin Andrews

Kristin Andrews, PhD

Chemistry
Alex Balcom

Alex Balcom, MBA, CPA

Chief Financial Officer
Jim Burgeson

Jim Burgeson

Pharmaceutical Development
Kristi Byrnes

Kristi Byrnes

Quality
Matthew Campbell

Matthew Campbell

Pharmaceutical Development
Liz Candido

Liz Candido

Operations
Stephanie Ceballos

Stephanie Ceballos

Information Technology
Smruti Chaudhari

Smruti Chaudhari, PhD

Pharmaceutical Development
Sibao Chen

Sibao Chen, PhD

Pharmaceutical Development
Paula Chubet

Paula Chubet

Legal
Christopher Cooper

Christopher Cooper, PhD

Pharmaceutical Development
Crespo-Jessica

Jess Crespo, CPA

Finance
Steve Critchley

Steve Critchley

Pharmaceutical Development
Shannon Dauksis

Shannon Dauksis, PharmD

Program Management
DeLaRosa-Rachel

Rachel DeLaRosa

Clinical
Philip Engel

Philip Engel

Information Technology
Jenn Fairbanks

Jenn Fairbanks

Clinical
Wenzhe Fan

Wenzhe Fan, PhD

Pharmaceutical Development
Scott Faulhaber

Scott Faulhaber

Clinical Supply Chain
Jesus Garza

Jesus Garza

Finance
Baudouin Gerard

Baudouin Gerard, PhD

Pharmaceutical Development
Gibson Tina

Tina Gibson

Quality
Nurisha Gobin

Nurisha Gobin, PharmD, RPh

Regulatory Affairs
Andrew Havens

Andrew Havens

Legal
Sophie Higgins

Sophie Higgins

Regulatory Affairs
Joshua Horan

Joshua Horan, PhD

Vice President, Chemistry
Tina Kehrig

Tina Kehrig

Clinical
Ray Kemper

Ray Kemper, PhD

Translational Development
Gloria (Glo) Kennedy

Gloria (Glo) Kennedy, RN

Clinical
Jason Kropp

Jason Kropp

Pharmaceutical Development
Shashank Kulkarni

Shashank Kulkarni, PhD

Chemistry
Joshua Lance

Joshua Lance, JD

Legal
Benjamin Lane

Benjamin Lane, PhD

Senior Vice President, Technical Operations
Lidya Le

Lidya Le

Clinical
Jeffrey Lee

Jeffrey Lee

Information Technology
Megan Lichtenfels

Megan Lichtenfels, CPA

Finance
Jessie Lin

Jessie Lin

Vice President, Corporate Strategy & Portfolio Management
Lister-Chelcie

Chelcie Lister

Corporate Development
Allison Magnan

Allison Magnan

Quality
Joseph Magrino

Joseph Magrino, PhD

Biology
Morgan Maiola

Morgan Maiola

Quality
Sowjanya Mangipudi

Sowjanya Mangipudi

Clinical
Christian Martin

Christian Martin

Translational Development
Nathan McConarty

Nathan McConarty, JD

Legal
Stephen McNamara

Stephen McNamara

Finance
Scot Mente

Scot Mente, PhD

Chemistry
Matthew Metivier

Matthew Metivier

Senior Vice President,
Human Resources
Ashlin Miller

Ashlin Miller, PharmD

Program Management
Deb Miller

Deb Miller, PhD, JD

Chief Legal Officer
Tuan Minh Nguyen

Tuan Minh Nguyen, PhD

Biology
Darlene Noci

Darlene Noci, ALM

Chief Development Officer
Marco Palencia

Marco Palencia

Clinical
Henry Pelish

Henry Pelish, PhD

Senior Vice President, Drug Discovery

James Porter, PhD

Chief Executive Officer
Bob Prytko

Bob Prytko

Pharmaceutical Development
Gosia Riley

Gosia Riley

Clinical
Jose Rios Lizarraga

José Rios Lizarraga, PhD

Pharmaceutical Development
Amy Rochford

Amy Rochford

Clinical
Mikhaila Ruth

Mikhaila Ruth

Human Resources
Prabjyot Sachdev

Prabjyot Sachdev

Corporate Development
Manoj Samant

Manoj Samant, PhD

Clinical
Danieska Sandino

Danieska Sandino

Clinical
Christine Schneeberg

Christine Schneeberg

Clinical Supply Chain
Maureen Secord

Maureen Secord

Pharmaceutical Development
Sizemore Jacob

Jacob Sizemore, PhD

Pharmaceutical Development
Greg Smith

Greg Smith

Regulatory Affairs
John Soglia

John Soglia, PhD

Senior Vice President, Translational Development
Kevin Staffin

Kevin Staffin

Quality
Yuting Sun

Yuting Sun, PhD

Biology
Wint Swe

Wint Swe

Clinical
Anupong Tangpeerachaikul

Anupong Tangpeerachaikul, PhD

Biology
Christopher Turner

Christopher Turner, MD

Chief Medical Officer
Vivek Upadhyay

Vivek Upadhyay, MD

Clinical
Virginia Vetter

Virginia Vetter

Regulatory Affairs
Brenda Vienneau

Brenda Vienneau, CPA, CMA

Finance
Wash Michael

Michael Walsh, PhD

Biology
Stacia Wegst Uhrich

Stacia Wegst-Uhrich, PhD

Pharmaceutical Development
Carla Whalen

Carla Whalen

Human Resources
Wilson Lindsey

Lindsey Wilson

Clinical
Perrin Wilson

Perrin Wilson, PhD

Senior Vice President,
Business Development & Strategy
Jimmy Yung

Jimmy Yung

Finance
Viola Zhu

Viola Zhu, MD, PhD

Clinical
Fareya Zubair

Fareya Zubair

Regulatory Affairs
Emily Darbant Conley

Emily Drabant Conley, PhD

Chief Executive Officer, Renasant Bio
Gary Gilliland

Gary Gilliland, MD, PhD

Independent Board Member
Andrew A.F. Hack

Andrew A. F. Hack, MD, PhD

Managing Director, Bain Capital Life Sciences
Michael Meyers

Michael Meyers, MD, PhD

Chief Medical Officer, Flare Therapeutics
Joseph Pearlberg

Joseph Pearlberg, MD, PhD

VP of Scientific Affairs, Deerfield Management
Anna Protopapas

Anna Protopapas

Independent Board Member
Matthew D. Shair

Matthew D. Shair, PhD

Founder, Head Scientific Advisor
Sapna Srivastava

Sapna Srivastava, PhD

Independent Board Member
Cameron Wheeler

Cameron Wheeler, PhD

Partner, Deerfield Management

Our clinical trials

Learn More
Read the latest news

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024